Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073511 | 0.98 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL5860807 | 0.98 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL939043 | 0.98 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL8058962 | 0.98 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL487425 | 0.98 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| SCHEMBL939042 | 0.98 | DPP4 (0.56) | DPP4LMNAMAPK1CYP2D6SRC | |
| Hydrochloric Acid SCHEMBL8073692 | 0.96 | DPP4 (0.54) | DPP4LMNAMAPK1CYP2D6SRC | |
| Hydrochloric Acid SCHEMBL5860803 | 0.96 | DPP4 (0.54) | DPP4LMNAMAPK1CYP2D6SRC | |
| Hydrochloric Acid SCHEMBL3184809 | 0.96 | DPP4 (0.54) | DPP4LMNAMAPK1CYP2D6SRC | |
| Cadaverine Tartrate SCHEMBL30110790 | 0.89 | DPP4 (0.64) | DPP4LMNAMAPK1CYP2D6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034178-B2 | Process for the production of 3-phenylisoserine | ALTANA PHARMA AG (DE) | 2006-04-25 | — | — | US | disclosed |
| US-20060041163-A1 | Process for the production of optically active 3-phenylisoserine | ALTANA PHARMA AG | 2006-02-23 | — | — | US | disclosed |
| EP-1463699-A2 | PROCESS FOR THE PRODUCTION OF 3-PHENYLISOSERINE | ALTANA Pharma AG (DE) | 2004-10-06 | — | — | EP | disclosed |
| US-20040176460-A1 | Use of L-(+)-tartaric acid in the separation of (R, R)-3-phenylisoserine or a derivative thereof from racemic mixtures | ALTANA PHARMA AG (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2003003804-A2 | PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE 3-PHENYLISOSERINE | ALTANA PHARMA AG (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041163-A1 | Process for the production of optically active 3-phenylisoserine | PSPH, PCMT1, SRR | DPP4 709/4885LMNA 4291/4885MAPK1 2016/4885 |
| US-20040176460-A1 | Use of L-(+)-tartaric acid in the separation of (R, R)-3-phenylisoserine or a derivative thereof from racemic mixtures | SRR, PCMT1, PSAT1 | DPP4 1579/4885LMNA 3896/4885MAPK1 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.